Captrust Financial Advisors Has $6.70 Million Stake in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

Captrust Financial Advisors raised its stake in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 2.2% in the 3rd quarter, Holdings Channel reports. The firm owned 14,409 shares of the pharmaceutical company’s stock after purchasing an additional 307 shares during the quarter. Captrust Financial Advisors’ holdings in Vertex Pharmaceuticals were worth $6,701,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the stock. Whalen Wealth Management Inc. bought a new position in Vertex Pharmaceuticals during the third quarter worth $662,000. Creative Planning raised its position in shares of Vertex Pharmaceuticals by 5.3% in the 2nd quarter. Creative Planning now owns 79,117 shares of the pharmaceutical company’s stock worth $37,084,000 after acquiring an additional 3,998 shares in the last quarter. Mizuho Securities USA LLC lifted its stake in shares of Vertex Pharmaceuticals by 289.0% in the 3rd quarter. Mizuho Securities USA LLC now owns 77,393 shares of the pharmaceutical company’s stock valued at $35,994,000 after purchasing an additional 57,497 shares during the period. Blue Trust Inc. boosted its position in shares of Vertex Pharmaceuticals by 640.0% during the 2nd quarter. Blue Trust Inc. now owns 1,443 shares of the pharmaceutical company’s stock valued at $676,000 after purchasing an additional 1,248 shares in the last quarter. Finally, Manning & Napier Advisors LLC acquired a new stake in Vertex Pharmaceuticals during the second quarter worth approximately $74,213,000. 90.96% of the stock is owned by institutional investors and hedge funds.

Vertex Pharmaceuticals Stock Down 0.5 %

Shares of NASDAQ:VRTX opened at $465.73 on Tuesday. Vertex Pharmaceuticals Incorporated has a 1 year low of $347.51 and a 1 year high of $519.88. The company has a market capitalization of $119.94 billion, a PE ratio of -234.04 and a beta of 0.36. The business has a fifty day moving average price of $472.87 and a two-hundred day moving average price of $475.06. The company has a debt-to-equity ratio of 0.01, a current ratio of 2.47 and a quick ratio of 2.20.

Vertex Pharmaceuticals (NASDAQ:VRTX) last issued its quarterly earnings results on Monday, November 4th. The pharmaceutical company reported $4.38 earnings per share for the quarter, topping analysts’ consensus estimates of $3.61 by $0.77. The company had revenue of $2.77 billion for the quarter, compared to the consensus estimate of $2.69 billion. Vertex Pharmaceuticals had a negative net margin of 4.52% and a negative return on equity of 1.91%. The firm’s quarterly revenue was up 11.6% on a year-over-year basis. During the same period in the previous year, the firm earned $3.67 EPS. Analysts forecast that Vertex Pharmaceuticals Incorporated will post -1.83 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several equities analysts have issued reports on the company. Scotiabank boosted their price target on Vertex Pharmaceuticals from $480.00 to $486.00 and gave the company a “sector perform” rating in a research note on Tuesday, November 5th. HC Wainwright reiterated a “buy” rating and set a $600.00 target price on shares of Vertex Pharmaceuticals in a research report on Monday, October 21st. Royal Bank of Canada raised their price target on shares of Vertex Pharmaceuticals from $437.00 to $451.00 and gave the stock a “sector perform” rating in a report on Tuesday, November 5th. StockNews.com lowered shares of Vertex Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Thursday, November 21st. Finally, Raymond James restated a “market perform” rating on shares of Vertex Pharmaceuticals in a research note on Thursday, October 10th. Three research analysts have rated the stock with a sell rating, eight have issued a hold rating, eighteen have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, Vertex Pharmaceuticals currently has an average rating of “Moderate Buy” and an average price target of $504.38.

Vertex Pharmaceuticals Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.